A Phase 3 interventional study of Orforglipron and Placebo in Obesity, Overweight and Overweight or Obesity, sponsored by Eli Lilly and Company. Active, not recruiting at 138 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-14.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing orforglipron in Obesity — 4 open to participants now, 10 under way, 9 of them phase 3. orforglipron · Obesity.
Among the 22 studies testing orforglipron in Obesity, this one has the largest enrollment, is one of 6 that started in 2023, is one of 14 in phase 3, and was the 5th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →4 of the 22 studies testing orforglipron in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Belgium, Brazil and 10 more countries
Ages 6–17
Eli Lilly and Company · Sites in United States, Israel, Italy and 3 more countries
Ages 12–17
Eli Lilly and Company · Sites in China
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18–80
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, orforglipron is the treatment under test here. Read study by study →
22 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,127 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 324 across the 22 interventional studies. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 22 have an industry lead sponsor. The 2 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
118 studies in Obesity by Eli Lilly and Company: 31 open now, 55 under way, 30 of them phase 3. Of 61 finished, 29 (48%) have results posted.
Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 2nd largest by enrollment of the 117 interventional ones that give a count, is one of 21 that started in 2023, is one of 51 in phase 3, reaches primary completion later than 0 of the 54 other live ones, and was the 29th registered.
Eli Lilly and Company’s Obesity studies by the year they started, since 2009.
5 of the studies testing orforglipron in Obesity that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
| NCT06972459Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity | 2027-08 |
| NCT06972472Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | 2027-08 |
| NCT06948435Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 22 studies testing orforglipron in Obesity, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 118 in Obesity:
This tab as a report to print or save as PDF → With an account.
This study will investigate the efficacy and safety of once daily oral orforglipron in adult participants with obesity or overweight with weight-related comorbidities. The study has two phases: a main phase and an extension phase. The main phase of the study lasted 72 weeks. Participants with prediabetes will continue in the extension for another 2 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have a
≥27.0 kg/m² and presence of at least 1 of the following weight-related comorbidities (treated or untreated) at screening:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received orforglipron-matching placebo, administered orally once daily (QD), for a period of 72 weeks.
Drug: Placebo
Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received orforglipron, administered orally QD, starting at a dose of 1 milligrams (mg) and escalated every 4 weeks until reaching a dose of 6 mg at week 8, which was then maintained up to week 72.
Drug: Orforglipron
Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received orforglipron, administered orally QD, starting at a dose of 1 mg and escalated every 4 weeks until reaching a dose of 12 mg at week 12, which was then maintained up to week 72.
Drug: Orforglipron
Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received orforglipron, administered orally QD, starting at a dose of 1 mg and escalated every 4 weeks until reaching a dose of 36 mg at week 20, which was then maintained up to week 72.
Drug: Orforglipron
Administered orally.
Also known as: LY3502970
Administered orally.
Percent Change From Baseline in Body Weight (Primary Treatment Period)
Values represented under "Least Squares (LS) Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with geographic region, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of Sex (female, male) and prediabetes status (yes, no). Variance-covariance structure for change from baseline was unstructured.
Time frame: Baseline, Week 72
Change From Baseline in Waist Circumference (Primary Treatment Period)
Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with geographic region, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of Sex (female, male) and prediabetes status (yes, no). Variance-covariance structure for change from baseline was unstructured.
Time frame: Baseline, Week 72
Change From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment Period
Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with geographic region, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of Sex (female, male) and prediabetes status (yes, no). Variance-covariance structure for change from baseline was unstructured.
Time frame: Baseline, Week 72
Percent Change From Baseline in Non-High Density Lipoprotein (Non-HDL) Cholesterol (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment Period
Values represented under "Geometric LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with log (Actual Measurement/Baseline) = geographic region, log(baseline) by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of Sex (female, male) and prediabetes status (yes, no). Variance-covariance structure for change from baseline was unstructured.
Time frame: Baseline, Week 72
Percent Change From Baseline in Triglycerides (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment Period
Values represented under "Geometric LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with log (Actual Measurement/Baseline) = geographic region, log(baseline) by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of Sex (female, male) and prediabetes status (yes, no). Variance-covariance structure for change from baseline was unstructured.
Time frame: Baseline, Week 72
Change From Baseline in HbA1c (Primary Treatment Period)
* Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A, measured to reflect average plasma glucose concentration over prolonged periods of time. * Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with geographic region, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of Sex (female, male) and prediabetes status (yes, no). Variance-covariance structure for change from baseline was unstructured.
Time frame: Baseline, Week 72
Change From Baseline in Fasting Serum Glucose (FSG) (Primary Treatment Period)
Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with geographic region, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of Sex (female, male) and prediabetes status (yes, no). Variance-covariance structure for change from baseline was unstructured.
Time frame: Baseline, Week 72
Percent Change From Baseline in Fasting Insulin (Primary Treatment Period)
* Fasting insulin is a blood test that measures the level of insulin in the blood after fasting. * Values represented under "Geometric LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with log (Actual Measurement/Baseline) = geographic region, log(baseline) by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of Sex (female, male) and prediabetes status (yes, no). Variance-covariance structure for change from baseline was unstructured.
Time frame: Baseline, Week 72
Change From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment Period
Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with geographic region, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of Sex (female, male) and prediabetes status (yes, no). Variance-covariance structure for change from baseline was unstructured.
Time frame: Baseline, Week 72
Change From Baseline in Short Form-36 Health Survey Version 2 (SF-36v2) Acute Form (Physical Component and Mental Component) Scores - (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment Period
The SF-36v2 is a participant-reported measure designed to assess health status using 36 items across 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The physical functioning domain assesses limitations due to health "now," whereas the remaining domains assess functioning "in the past week." Each domain is scored individually, and information from these 8 domains is aggregated into 2 health component summary scores, the Physical Component Summary and Mental Component Summary. Items are answered on Likert scales of varying lengths (3-point, 5-point, or 6-point scales). Scoring of each domain and both summary scores are norm based and presented in the form of T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores.
Time frame: Baseline, Week 72
Percent Change From Baseline in Body Weight (Primary and Additional Treatment Periods: Participants With Prediabetes at Randomization)
Time frame: Baseline, Week 176
Time to Onset of Type 2 Diabetes (Primary and Additional Treatment Periods: Participants With Prediabetes at Randomization)
Time frame: Baseline through Week 176, Baseline through Week 190
Results reported here are based on a data cutoff of 30 July 2025, corresponding to completion of the Primary Treatment Period. Final results, including the Additional Treatment Period, will be reported at the time of study completion results posting, no later than October 2028.
| Milestone | Placebo | 6 mg Orforglipron | 12 mg Orforglipron | 36 mg Orforglipron |
|---|---|---|---|---|
| Started | 949 | 723 | 725 | 730 |
| Received at least one dose of study drug | 948 | 723 | 724 | 728 |
| Participants with normoglycemia at randomization | 605 | 465 | 465 | 465 |
| Participants with prediabetes at randomization | 344 | 258 | 260 | 265 |
| Completed | 768 | 625 | 630 | 639 |
| Not completed | 181 | 98 | 95 | 91 |
| Withdrew: Withdrawal by subject | 89 | 38 | 44 | 34 |
| Withdrew: Lost to follow-up | 26 | 14 | 13 | 22 |
| Withdrew: Adverse event | 10 | 8 | 13 | 16 |
| Withdrew: Site terminated by sponsor | 12 | 15 | 6 | 8 |
| Withdrew: Protocol deviation | 9 | 12 | 10 | 8 |
| Withdrew: Lack of efficacy | 26 | 2 | 1 | 0 |
| Withdrew: Pregnancy | 3 | 5 | 6 | 1 |
| Withdrew: Other - as reported by the investigator | 2 | 3 | 0 | 1 |
| Withdrew: Physician decision | 3 | 0 | 1 | 1 |
| Withdrew: Death | 1 | 1 | 1 | 0 |
Values represented under "Least Squares (LS) Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with geographic region, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of Sex (female, male) and prediabetes status (yes, no). Variance-covariance structure for change from baseline was unstructured.
| percent change | Placebo | 6 mg Orforglipron | 12 mg Orforglipron | 36 mg Orforglipron |
|---|---|---|---|---|
| Percent Change From Baseline in Body Weight (Primary Treatment Period) | -0.87 ± 0.247 | -7.82 ± 0.302 | -9.27 ± 0.335 | -12.35 ± 0.364 |
Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with geographic region, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of Sex (female, male) and prediabetes status (yes, no). Variance-covariance structure for change from baseline was unstructured.
| centimeters | Placebo | 6 mg Orforglipron | 12 mg Orforglipron | 36 mg Orforglipron |
|---|---|---|---|---|
| Change From Baseline in Waist Circumference (Primary Treatment Period) | -2.09 ± 0.260 | -7.54 ± 0.305 | -9.00 ± 0.318 | -11.13 ± 0.318 |
Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with geographic region, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of Sex (female, male) and prediabetes status (yes, no). Variance-covariance structure for change from baseline was unstructured.
| millimeters of mercury (mmHg) | Placebo | Pooled 6 mg/12 mg/36 mg Orforglipron |
|---|---|---|
| Change From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment Period | -0.78 ± 0.404 | -6.14 ± 0.283 |
Values represented under "Geometric LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with log (Actual Measurement/Baseline) = geographic region, log(baseline) by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of Sex (female, male) and prediabetes status (yes, no). Variance-covariance structure for change from baseline was unstructured.
| percent change | Placebo | Pooled 6 mg/12 mg/36 mg Orforglipron |
|---|---|---|
| Percent Change From Baseline in Non-High Density Lipoprotein (Non-HDL) Cholesterol (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment Period | -1.41 ± 0.715 | -7.57 ± 0.454 |
Values represented under "Geometric LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with log (Actual Measurement/Baseline) = geographic region, log(baseline) by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of Sex (female, male) and prediabetes status (yes, no). Variance-covariance structure for change from baseline was unstructured.
| percent change | Placebo | Pooled 6 mg/12 mg/36 mg Orforglipron |
|---|---|---|
| Percent Change From Baseline in Triglycerides (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment Period | -4.8 ± 1.21 | -16.4 ± 0.74 |
* Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A, measured to reflect average plasma glucose concentration over prolonged periods of time. * Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with geographic region, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of Sex (female, male) and prediabetes status (yes, no). Variance-covariance structure for change from baseline was unstructured.
| percentage of HbA1c | Placebo | 6 mg Orforglipron | 12 mg Orforglipron | 36 mg Orforglipron |
|---|---|---|---|---|
| Change From Baseline in HbA1c (Primary Treatment Period) | -0.03 ± 0.010 | -0.31 ± 0.010 | -0.31 ± 0.010 | -0.38 ± 0.011 |
Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with geographic region, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of Sex (female, male) and prediabetes status (yes, no). Variance-covariance structure for change from baseline was unstructured.
| milligram per deciliter (mg/dL) | Placebo | 6 mg Orforglipron | 12 mg Orforglipron | 36 mg Orforglipron |
|---|---|---|---|---|
| Change From Baseline in Fasting Serum Glucose (FSG) (Primary Treatment Period) | 0.28 ± 0.407 | -7.68 ± 0.341 | -8.70 ± 0.334 | -9.25 ± 0.378 |
* Fasting insulin is a blood test that measures the level of insulin in the blood after fasting. * Values represented under "Geometric LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with log (Actual Measurement/Baseline) = geographic region, log(baseline) by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of Sex (female, male) and prediabetes status (yes, no). Variance-covariance structure for change from baseline was unstructured.
| percent change | Placebo | 6 mg Orforglipron | 12 mg Orforglipron | 36 mg Orforglipron |
|---|---|---|---|---|
| Percent Change From Baseline in Fasting Insulin (Primary Treatment Period) | -7.30 ± 2.211 | -20.64 ± 1.967 | -23.87 ± 2.047 | -32.78 ± 1.875 |
Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with geographic region, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of Sex (female, male) and prediabetes status (yes, no). Variance-covariance structure for change from baseline was unstructured.
| millimeters of mercury (mmHg) | Placebo | Pooled 6 mg/12 mg/36 mg Orforglipron |
|---|---|---|
| Change From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment Period | -0.93 ± 0.273 | -2.53 ± 0.194 |
The SF-36v2 is a participant-reported measure designed to assess health status using 36 items across 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The physical functioning domain assesses limitations due to health "now," whereas the remaining domains assess functioning "in the past week." Each domain is scored individually, and information from these 8 domains is aggregated into 2 health component summary scores, the Physical Component Summary and Mental Component Summary. Items are answered on Likert scales of varying lengths (3-point, 5-point, or 6-point scales). Scoring of each domain and both summary scores are norm based and presented in the form of T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores.
| T-score | Placebo | Pooled 6 mg/12 mg/36 mg Orforglipron |
|---|---|---|
| Physical Component Score | 0.76 ± 0.232 | 2.28 ± 0.131 |
| Mental Component Score | -1.08 ± 0.244 | -0.65 ± 0.157 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over Baseline Up to Week 74. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 1/948 (0.1%) | 46/948 (4.9%) | 557/948 (58.8%) |
| 6 mg Orforglipron | 1/723 (0.1%) | 40/723 (5.5%) | 520/723 (71.9%) |
| 12 mg Orforglipron | 1/724 (0.1%) | 39/724 (5.4%) | 544/724 (75.1%) |
| 36 mg Orforglipron | 0/728 (0%) | 28/728 (3.8%) | 550/728 (75.5%) |
| Event | Placebo | 6 mg Orforglipron | 12 mg Orforglipron | 36 mg Orforglipron |
|---|---|---|---|---|
| UreterolithiasisRenal and urinary disorders | 0/948 | 3/723 | 0/724 | 0/728 |
| Cholecystitis acuteHepatobiliary disorders | 1/948 | 1/723 | 1/724 | 3/728 |
| Testicular germ cell tumour mixedNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/341 | 0/254 | 1/258 | 0/264 |
| Acute myocardial infarctionCardiac disorders | 2/948 | 2/723 | 0/724 | 1/728 |
| NephrolithiasisRenal and urinary disorders | 2/948 | 2/723 | 1/724 | 0/728 |
| Obstructive pancreatitisGastrointestinal disorders | 0/948 | 0/723 | 2/724 | 0/728 |
| Cholecystitis chronicHepatobiliary disorders | 1/948 | 0/723 | 2/724 | 0/728 |
| Dengue feverInfections and infestations | 0/948 | 0/723 | 2/724 | 0/728 |
| Deep vein thrombosisVascular disorders | 0/948 | 0/723 | 2/724 | 0/728 |
| Coronary artery diseaseCardiac disorders | 0/948 | 0/723 | 0/724 | 2/728 |
| Event | Placebo | 6 mg Orforglipron | 12 mg Orforglipron | 36 mg Orforglipron |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 99/948 | 209/723 | 260/724 | 245/728 |
| ConstipationGastrointestinal disorders | 88/948 | 156/723 | 216/724 | 185/728 |
| VomitingGastrointestinal disorders | 33/948 | 94/723 | 155/724 | 175/728 |
| DiarrhoeaGastrointestinal disorders | 91/948 | 152/723 | 165/724 | 168/728 |
| DyspepsiaGastrointestinal disorders | 47/948 | 95/723 | 117/724 | 103/728 |
| Upper respiratory tract infectionInfections and infestations | 103/948 | 75/723 | 75/724 | 64/728 |
| HeadacheNervous system disorders | 71/948 | 62/723 | 75/724 | 71/728 |
| InfluenzaInfections and infestations | 73/948 | 68/723 | 58/724 | 44/728 |
| Abdominal distensionGastrointestinal disorders | 32/948 | 52/723 | 68/724 | 62/728 |
| NasopharyngitisInfections and infestations | 74/948 | 55/723 | 61/724 | 47/728 |
All randomized participants.
| Age, Continuous(years) | Placebo | 6 mg Orforglipron | 12 mg Orforglipron | 36 mg Orforglipron | Total |
|---|---|---|---|---|---|
| Mean | 45.1 ± 11.9 | 44.9 ± 12.1 | 45.4 ± 12.6 | 44.9 ± 11.9 | 45.1 ± 12.1 |
| Sex: Female, Male(Participants) | Placebo | 6 mg Orforglipron | 12 mg Orforglipron | 36 mg Orforglipron | Total |
|---|---|---|---|---|---|
| Female | 608 | 469 | 467 | 465 | 2009 |
| Male | 341 | 254 | 258 | 265 | 1118 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | 6 mg Orforglipron | 12 mg Orforglipron | 36 mg Orforglipron | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 369 | 273 | 275 | 258 | 1175 |
| Not Hispanic or Latino | 572 | 443 | 441 | 467 | 1923 |
| Unknown or Not Reported | 8 | 7 | 9 | 5 | 29 |
| Race (NIH/OMB)(Participants) | Placebo | 6 mg Orforglipron | 12 mg Orforglipron | 36 mg Orforglipron | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 4 | 2 | 3 | 2 | 11 |
| Asian | 267 | 202 | 201 | 214 | 884 |
| Native Hawaiian or Other Pacific Islander | 2 | 0 | 1 | 0 | 3 |
| Black or African American | 72 | 68 | 60 | 67 | 267 |
| White | 539 | 408 | 405 | 394 | 1746 |
| More than one race | 54 | 35 | 45 | 47 | 181 |
| Unknown or Not Reported | 11 | 8 | 10 | 6 | 35 |
| Region of Enrollment(Participants) | Placebo | 6 mg Orforglipron | 12 mg Orforglipron | 36 mg Orforglipron | Total |
|---|---|---|---|---|---|
| Brazil | 273 | 203 | 203 | 205 | 884 |
| China | 89 | 69 | 69 | 69 | 296 |
| India | 20 | 13 | 13 | 16 | 62 |
| Japan | 96 | 75 | 74 | 77 | 322 |
| Slovakia | 74 | 56 | 58 | 58 | 246 |
| South Korea | 27 | 21 | 20 | 18 | 86 |
| Spain | 95 | 69 | 72 | 69 | 305 |
| Taiwan | 25 | 17 | 18 | 20 | 80 |
| United States | 250 | 200 | 198 | 198 | 846 |
| Baseline Body Weight(kilograms (kg)) | Placebo | 6 mg Orforglipron | 12 mg Orforglipron | 36 mg Orforglipron | Total |
|---|---|---|---|---|---|
| Mean | 103.92 ± 22.03 | 103.18 ± 21.65 | 102.18 ± 21.58 | 103.10 ± 23.15 | 103.16 ± 22.11 |
Showing the first 100 of 138 sites across 10 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jun 2023 to primary completion in Jul 2025, 25 months.
Results were first posted in Aug 2026, 1 year after primary completion.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 25 months is above that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Orforglipron